Human ADA Protein

<strong>Human ADA Protein</strong>_x000D_ <strong>Catalog number:</strong> B2011492_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 50 µg_x000D_ <strong>Molecular Weight or Concentration:</strong> 0.5 mg/mL_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20 °C_x000D_ <strong>Keywords:</strong> ADA protein (His tag), ADA1 protein, Adenosine aminohydrolase protein_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Atiqi S, Hooijberg F, Loeff FC, Rispens T, Wolbink GJ. Immunogenicity of TNF-Inhibitors Front Immunol. 2020 Feb 26;11:312._x000D_ 2: Liu L. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins Protein Cell. 2018 Jan;9(1):15-32._x000D_ 3: Garcês S, Demengeot J. The Immunogenicity of Biologic Therapies Curr Probl Dermatol. 2018;53:37-48._x000D_ 4: Kimura A, Takekoshi A, Yoshikura N, Hayashi Y, Shimohata T. Clinical characteristics of autoimmune GFAP astrocytopathy J Neuroimmunol. 2019 Jul 15;332:91-98._x000D_ 5: American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019 Diabetes Care. 2019 Jan;42(Suppl 1):S90-S102._x000D_ 6: Zoghbi J, Xu Y, Grabert R, Theobald V, Richards S. A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays J Immunol Methods. 2015 Nov;426:62-9._x000D_ 7: Banfield C, Rudin D, Bhattacharya I, Goteti K, Li G, Hassan-Zahraee M, Brown LS, Hung KE, Pawlak S, Lepsy C. First-in-human, randomized dose-escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF-06480605 in healthy subjects Br J Clin Pharmacol. 2020 Apr;86(4):812-824._x000D_ 8: De Groot AS, Scott DW. Immunogenicity of protein therapeutics Trends Immunol. 2007 Nov;28(11):482-90._x000D_ 9: Meunier S, de Bourayne M, Hamze M, Azam A, Correia E, Menier C, Maillère B. Specificity of the T Cell Response to Protein Biopharmaceuticals Front Immunol. 2020 Jul 22;11:1550._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/24764037">10: Shankar G, Arkin S, Cocea L, Devanarayan V, Kirshner S, Kromminga A, Quarmby V, Richards S, Schneider CK, Subramanyam M, Swanson S, Verthelyi D, Yim S; American Association of Pharmaceutical Scientists. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations AAPS J. 2014 Jul;16(4):658-73. </a>_x000D_ _x000D_ <strong>Products Related to Human ADA Protein can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>